Mikhail Lichinitser

2003–2019 年に発表

28
論文数
20,663
被引用数
27
h 指数
28
i10 指数

被引用数

Mikhail Lichinitser の年別被引用数1948 年: 被引用 1 件1999 年: 被引用 1 件2003 年: 被引用 1 件2004 年: 被引用 9 件2005 年: 被引用 23 件2006 年: 被引用 67 件2007 年: 被引用 102 件2008 年: 被引用 113 件2009 年: 被引用 161 件2010 年: 被引用 213 件2011 年: 被引用 227 件2012 年: 被引用 213 件2013 年: 被引用 255 件2014 年: 被引用 206 件2015 年: 被引用 202 件2016 年: 被引用 214 件2017 年: 被引用 173 件2018 年: 被引用 172 件2019 年: 被引用 626 件2020 年: 被引用 647 件2021 年: 被引用 554 件2022 年: 被引用 350 件2023 年: 被引用 253 件2024 年: 被引用 365 件2025 年: 被引用 153 件2026 年: 被引用 3 件1949〜1998 年は被引用が無いため表示していません2000〜2002 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,116 件、この内訳の 22.6%中国: 引用元論文 642 件、この内訳の 6.9%イギリス: 引用元論文 626 件、この内訳の 6.7%イタリア: 引用元論文 592 件、この内訳の 6.3%ドイツ: 引用元論文 517 件、この内訳の 5.5%フランス: 引用元論文 416 件、この内訳の 4.4%オーストラリア: 引用元論文 350 件、この内訳の 3.7%スペイン: 引用元論文 343 件、この内訳の 3.7%カナダ: 引用元論文 330 件、この内訳の 3.5%日本: 引用元論文 326 件、この内訳の 3.5%スイス: 引用元論文 306 件、この内訳の 3.3%オランダ: 引用元論文 281 件、この内訳の 3%
0%22.6%その他 26.9%

分野

  • Medicine69.7%
  • Biochemistry, Genetics and Molecular Biology24.8%
  • Immunology and Microbiology2.2%
  • Computer Science0.7%
  • Materials Science0.5%
  • Mathematics0.4%
  • その他1.7%

トピック

  • HER2/EGFR in Cancer Research8.2%
  • Breast Cancer Treatment Studies5.2%
  • Cancer Immunotherapy and Biomarkers4.9%
  • Colorectal Cancer Treatments and Studies4%
  • Cancer Treatment and Pharmacology3.4%
  • Advanced Breast Cancer Therapies3.3%
  • その他71%

共著者

全論文

検索で開く
  1. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2018 被引用: 1,853

  2. Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mirko Dolci, Richard D. Gelber - New England Journal of Medicine 2005 被引用: 5,098

  3. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

    著者: , , , , , , , , , , , , , , , , , , , - The Lancet 2010 被引用: 1,268

  4. Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

    著者: , , , , , , , , , , , , - Journal of Clinical Oncology 2008 被引用: 2,963

  5. Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study

    著者: , , , , , , , , , , , , , , - Journal of Clinical Oncology 2010 被引用: 1,593

  6. Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer

    著者: , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2009 被引用: 1,024

  7. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort

    著者: , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2014 被引用: 491

  8. Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer

    著者: , , , , , , , , , , , , , , - Journal of Clinical Oncology 2010 被引用: 633

  9. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2015 被引用: 262

  10. Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor

    著者: , , , , , , , , , - Journal of Clinical Oncology 2013 被引用: 418

  11. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial

    著者: , , , , , , , , , , , , , , - Annals of Oncology 2009 被引用: 777

  12. Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer

    著者: , , , , , , , , , , , , - Journal of Clinical Oncology 2008 被引用: 864

  13. Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial

    著者: , , , , , , , , , , , , , , - JNCI Journal of the National Cancer Institute 2013 被引用: 328

  14. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01)

    著者: , , , , , , , , , , , , , , - The Lancet Oncology 2013 被引用: 211

  15. Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Doris Augustin, Heiko Graf, Georg Heinrich, Hendrik Kroening, Sherko Küemmel, Volkmar Müller, Friedrich Overkamp, Tjoung‐Won Park‐Simon, Marcus Schmidt, Lidia Perlova-Griff, Christopher Wolf, Marco Colleoni, Alberto Ballestrero, Antônio Bernardo, Angela Stefania Ribecco, Luca Gianni, Giuseppe Curigliano, E. Brewczynska, Jacek Jassem, Vadim Shirinkin, Alexey Manikhas, В. В. Дворниченко, Mikhail Lichinitser, Semiglazov Vf, Guzel Mukhametshina, Irina Bulavina, Enrique Espinosa Arranz, Francisco Carabantes Ocón, Guillermo López-Vivanco, Javier Salvador Bofill, Ignacio Porras Quintela, Alfonso Sánchez Muñoz, Yolanda Fernández Pérez, Javier Cassinello Espinosa, Jose Alvarez, Rodrigo Lastra del Prado, LuisLa Cruz De Merino, José Manuel Pérez García, Santos Enrech Francés, Per Edlund, Bengt Norberg, Anna-Karin Wennstig, Pehr Lind, Nik Hauser, Christoph Tausch, Celalettin Camcı, Fikret Arpacı, Hüseyin Abalı, Rüçhan Uslu, Saad Tahir, Duncan Wheatley, Stephen Chan, Peter Barrett‐Lee, Karen McAdam, Richard Simcock, Russell Burcombe, Robert H. El-Maraghi, Nadia Califaretti, Silvana Spadafora, Sandeep Sehdev, Amer Sami, Sunil Verma - Annals of Oncology 2014 被引用: 176

  16. An attempt to prevent senescence: A mitochondrial approach

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - Biochimica et Biophysica Acta (BBA) - Bioenergetics 2008 被引用: 426

  17. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial

    著者: , , , , , , , , , , - The Lancet Oncology 2012 被引用: 346

  18. Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Stefan Suciu, Caroline Robert - European Journal of Cancer 2019 被引用: 86

  19. Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial

    著者: , , , , , , , , , - Journal of Clinical Oncology 2010 被引用: 565

  20. A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma

    著者: , , , , , , , , , , , - British Journal of Cancer 2013 被引用: 79

  21. HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant–adjuvant trastuzumab after 2 years of treatment-free follow-up

    著者: , , , , , , , , , , , , , , , - European Journal of Cancer 2016 被引用: 78

  22. First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study

    著者: , , , , , , , , , , , , , , - Journal of Clinical Oncology 2012 被引用: 262

  23. Comparison of Fulvestrant Versus Tamoxifen for the Treatment of Advanced Breast Cancer in Postmenopausal Women Previously Untreated With Endocrine Therapy: A Multinational, Double-Blind, Randomized Trial

    著者: , , , , , , , , , , - Journal of Clinical Oncology 2004 被引用: 425

  24. Randomized Phase III Study of High-Dose Fluorouracil Given As a Weekly 24-Hour Infusion With or Without Leucovorin Versus Bolus Fluorouracil Plus Leucovorin in Advanced Colorectal Cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952

    著者: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2003 被引用: 160